Novel approaches to intraperitoneal drug delivery.
The prolonged continuous intraperitoneal infusion of cytoarabin was studied in 28 courses. Only 9 courses were completed for the full period of 3 weeks. No cytoarabin was detected in the plasma of patients on any of these courses. The combination of intraperitoneal administration of methotrexate and dipyridamole did not show a synergistic interaction of these 2 substances. However, the addition of dipyridamole to etoposide showed a clear synergy between these 2 substances studied on a human ovarian carcinoma cell line.
Howell
S B
SB
Department of Medicine, University of California, San Diego La Jolla 92093.
Kirmani
S
S
Goel
R
R
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004176:Dipyridamole / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007263:Infusions, Parenteral / Q000295:instrumentation; D008134:Long-Term Care; D008727:Methotrexate / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents; D004176:Dipyridamole; D005047:Etoposide; D008727:Methotrexate